ArticleMolecular genetics and genomics : MGG2009
The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation.
Article in Molecular genetics and genomics : MGG, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.Gynecologic oncology reports · 2026Article
- Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer.International journal of molecular sciences · 2026Review
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- J2R/F4L deleted oncolytic vaccinia virus synergizes with tumor specific killer (ELANE) promotes antitumor immunity with superior safety.Frontiers in immunology · 2026Article
- Progress in the research and development of oncolytic virus therapies.Frontiers in pharmacology · 2026Review
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- PRO-Simat: Protein network simulation and design tool.Computational and structural biotechnology journal · 2023Article
- Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy.Cancers · 2022Article
- Genetic ancestry and population structure of vaccinia virus.NPJ vaccines · 2022Article
- Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy.Frontiers in pharmacology · 2022Review
- A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy.Frontiers in molecular biosciences · 2022Article
- Oncolytic Vaccinia Virus HarboringMarine drugs · 2021Article
- Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.BMC cancer · 2020Article
- Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.Oncolytic virotherapy · 2020Review
- lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer.Molecular therapy oncolytics · 2019Article
- Progress in gene therapy using oncolytic vaccinia virus as vectors.Journal of cancer research and clinical oncology · 2018Review
- The emerging role of oncolytic virus therapy against cancer.Chinese clinical oncology · 2018Review
- Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 withMolecular therapy oncolytics · 2017Article
- Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.Oncotarget · 2016Article
- Oncolytic viruses-immunotherapeutics on the rise.Journal of molecular medicine (Berlin, Germany) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical studies, but potential infection of other organs remains a safety concern. We present here genome comparisons between the de novo sequence of GLV-1h68, a recombinant VACV, and other VACVs. The identified differences in open reading frames (ORFs) include genes encoding host-range selection, virulence and immune modulation proteins, e.g., ankyrin-like proteins, serine proteinase inhibitor SPI-2/CrmA, tumor necrosis factor (TNF) receptor homolog CrmC, semaphorin-like and interleukin-1 receptor homolog proteins. Phylogenetic analyses indicate that GLV-1h68 is closest to Lister strains but has lost several ORFs present in its parental LIVP strain, including genes encoding CrmE and a viral Golgi anti-apoptotic protein, v-GAAP. The reduced pathogenicity of GLV-1h68 is confirmed in male mice bearing C6 rat glioma and in immunocompetent mice bearing B16-F10 murine melanoma. The contribution of foreign gene expression cassettes in the F14.5L, J2R and A56R loci is analyzed, in particular the contribution of F14.5L inactivation to the reduced virulence is demonstrated by comparing the virulence of GLV-1h68 with its F14.5L-null and revertant viruses. GLV-1h68 is a promising engineered VACV variant for anticancer therapy with tumor-specific replication, reduced pathogenicity and benign tissue tropism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.